Cell-free DNA Genomic and Epigenomic Analysis to Predict Survival in mCRPC Patients

Explore a conference talk from the Cancer Genomics Consortium's 2023 Annual Meeting focusing on cell-free DNA analysis in metastatic castration-resistant prostate cancer (mCRPC) patients. Delve into how genomic and epigenomic analysis of cell-free DNA can be used to predict survival outcomes in mCRPC patients undergoing AR-directed therapy. Learn about the latest advancements in clinical cancer genomics and their potential impact on patient diagnosis and treatment. Gain insights from speaker Pradeep Chauhan on this cutting-edge research in the field of cancer genomics. Understand the role of organizations like the Cancer Genomics Consortium in promoting best practices and education in clinical cancer genomic testing.

Cell-free DNA genomic and epigenomic analysis to predict survival in mCRPC patients